{
    "nct_id": "NCT04177810",
    "official_title": "A Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer",
    "inclusion_criteria": "Age â‰¥18 years.\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Have histologically or cytologically-proven ductal pancreatic cancer.\n* Have metastatic disease.\n* Have documented radiographic disease progression after previous systemic chemotherapy given in a neoadjuvant, adjuvant, locally advanced or metastatic setting.\n* Patients with the presence of at least one measurable lesion.\n* Willing to have to a tumor biopsy.\n* Life expectancy of greater than 3 months.\n* Patients must have adequate organ and marrow function defined by study - specified laboratory tests.\n* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.\n* Men must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known history or evidence of brain metastases.\n* Had chemotherapy, radiation, or steroids within 14 days prior to study treatment.\n* Have received any investigational drugs, a live vaccine, any allergen hyposensitization therapy, growth factors or major surgery within 28 days prior to study treatment.\n* Require any antineoplastic therapy.\n* Had surgery within 28 days of dosing of investigational agent.\n* Has received any prophylactic vaccine within 14 days of first dose of study drug.\n* History of prior treatment with anti-CXCR4.\n* Have used any systemic steroids within 14 days of study treatment.\n* Patients receiving growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin, within 14 days of study drug administration.\n* Hypersensitivity reaction to any monoclonal antibody.\n* Evidence of clinical or radiographic ascites.\n* Have clinically significant and/or malignant pleural effusion.\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Has an active known or suspected autoimmune disease.\n* Prior tissue or organ allograft or allogeneic bone marrow transplantation.\n* All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to grade 1 (National Cancer Institute Common Terminology Criteria for Adverse Events [CTCAE], version 5) or baseline before administration of study drug.\n* Infection with HIV or hepatitis B or C at screening.\n* Patient has a pulse oximetry of <92% on room air.\n* Patient is on supplemental home oxygen.\n* Has uncontrolled intercurrent acute or chronic medical illness or any use of illicit drugs or substance abuse.\n* Patient is unwilling or unable to follow the study schedule for any reason.\n* Woman who are pregnant or breastfeeding.\n* Have rapidly progressing disease, as judged by the investigator.\n* History of significant, recurrent, unexplained postural hypotension in the last 6 months.",
    "miscellaneous_criteria": ""
}